http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 08 Sep 2026 08:40:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/WestPark+Capital+Starts+Akebia+Therapeutics+%28AKBA%29+at+Buy/27033913.html <p>WestPark Capital initiates coverage on Akebia Therapeutics (NASDAQ: AKBA) with a Buy rating and a price target of $4.50.</p><p>For an analyst ratings summary and ratings history on Akebia Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AKBA">click here</a>. For more ratings news on Akebia Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AKBA&amp;type=analyst">click here</a>.</p><p>Shares of Akebia Therapeutics closed at $0.97 yesterday.</p> http://www.streetinsider.com/New+Coverage/WestPark+Capital+Starts+Akebia+Therapeutics+%28AKBA%29+at+Buy/27033913.html Tue, 08 Sep 2026 08:40:19 -0400 AKBA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+06++Filed+by%3A+Butler+John+P./26897903.html si-local-file:///var/storage/secattach/20260810/26897903.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+06++Filed+by%3A+Butler+John+P./26897903.html Mon, 10 Aug 2026 16:09:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+06++Filed+by%3A+Butler+John+P./26897903.html si-local-file:///var/storage/secattach/20260810/26897903.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+06++Filed+by%3A+Butler+John+P./26897903.html Mon, 10 Aug 2026 16:09:00 -0400 AKBA O.17530349 http://www.streetinsider.com/Downgrades/Leerink+Downgrades+Akebia+Therapeutics+%28AKBA%29+to+Market+Perform/26886864.html <p>Leerink analyst Roanna Ruiz downgraded Akebia Therapeutics (NASDAQ: AKBA) from Outperform to Market Perform with a price target of $1.00.</p><p>For an analyst ratings summary and ratings history on Akebia Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=AKBA">click here</a>. For more ratings news on Akebia Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=AKBA&amp;type=analyst">click here</a>.</p><p>Shares of Akebia Therapeutics closed at $0.95 yesterday.</p> http://www.streetinsider.com/Downgrades/Leerink+Downgrades+Akebia+Therapeutics+%28AKBA%29+to+Market+Perform/26886864.html Fri, 07 Aug 2026 06:11:45 -0400 AKBA http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Akebia+Therapeutics+%28AKBA%29/26878193.html <p>H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $6.00 price target on Akebia Therapeutics (NASDAQ: AKBA).</p><p>The analyst commented: "We view AKBA’s near-term strategy as being two-fold: (1) execute commercial efforts for oral tablet VAFSEO (vadadustat) for chronic kidney disease (CKD) anemia patients on dialysis; and (2) advance the kidney disease pipeline discussed below, which we view as offering upside beyond the VAFSEO and AURYXIA commercial contributions. Most importantly, we believe continued VAFSEO uptake by dialysis organizations (DOs) can be driven by the positive interim analysis from the VOICE trial demonstrating improved safety outcomes for CKD patients treated with http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Akebia+Therapeutics+%28AKBA%29/26878193.html Thu, 06 Aug 2026 06:58:55 -0400 AKBA http://www.streetinsider.com/Earnings/Akebia+Therapeutics+%28AKBA%29+Tops+Q2+EPS+by+1c/26875830.html <p>Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $49 million versus the consensus estimate of $50.93 million.</p><p>For earnings history and earnings-related data on Akebia Therapeutics (AKBA) <a href="http://www.streetinsider.com/ec_earnings.php?q=AKBA">click here</a>.</p> http://www.streetinsider.com/Earnings/Akebia+Therapeutics+%28AKBA%29+Tops+Q2+EPS+by+1c/26875830.html Wed, 05 Aug 2026 17:10:40 -0400 AKBA http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Akebia+Therapeutics%2C+++++++++++++++++/26875561.html si-local-file:///var/storage/secattach/20260805/26875561.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Akebia+Therapeutics%2C+++++++++++++++++/26875561.html Wed, 05 Aug 2026 16:58:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Akebia+Therapeutics%2C+++++++++++++++++/26875561.html si-local-file:///var/storage/secattach/20260805/26875561.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Akebia+Therapeutics%2C+++++++++++++++++/26875561.html Wed, 05 Aug 2026 16:58:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Akebia+Therapeutics%2C++++++For%3A+Jun+30/26874343.html si-local-file:///var/storage/secattach/20260805/26874343.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Akebia+Therapeutics%2C++++++For%3A+Jun+30/26874343.html Wed, 05 Aug 2026 16:11:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Akebia+Therapeutics%2C++++++For%3A+Jun+30/26874343.html si-local-file:///var/storage/secattach/20260805/26874343.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Akebia+Therapeutics%2C++++++For%3A+Jun+30/26874343.html Wed, 05 Aug 2026 16:11:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+05/26874232.html si-local-file:///var/storage/secattach/20260805/26874232.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+05/26874232.html Wed, 05 Aug 2026 16:09:00 -0400 AKBA O.17530349 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+05/26874232.html si-local-file:///var/storage/secattach/20260805/26874232.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Akebia+Therapeutics%2C++++++For%3A+Aug+05/26874232.html Wed, 05 Aug 2026 16:09:00 -0400 AKBA O.17530349 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html <p align="center"><em>Q2 2026 Vafseo® (vadadustat) net product revenues grew to </em><em>$21.3 million</em><em>; more than</em><em> 10,500 p</em><em>atients now on therapy</em></p> <p align="center"><em>Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; </em><em>initial data expected in 2027</em></p> <p align="center"><em>Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA </em></p> <p align="center"><em>Akebia to host conference call at 4:30 p.m. EDT on August 5, 2026 </em></p> http://www.streetinsider.com/Globe+Newswire/Akebia+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26873969.html Wed, 05 Aug 2026 16:05:00 -0400 A.04679647 A.50216944 AKBA O.01845845 O.17530349 O.60171739 http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26857642.html <p>CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PsJLcJcH8G8yJUXWm-mzTjElgNBozIopwQ7HMDp7-GCFPzYK8X8iQTbpcvrsdTqQkRnwyX2Pd21hcF2ZyHUchJi5zTnUSazwA7OWfXezq0M=" rel="nofollow" target="_blank">Akebia Therapeutics®, Inc.</a> (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 2 newly-hired employees options to purchase an aggregate of 61,000 shares of Akebia’s common stock on July 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The options have an exercise price of $1.32 per share, which is equal to the closing price of Akebia’s common http://www.streetinsider.com/Press+Releases/Akebia+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26857642.html Mon, 03 Aug 2026 16:05:00 -0400 AKBA O.17530349